Friday 6 November 2026 Export IMNM’s income statement to Excel — free account

Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue: +69.8%
EPS: −30.0%
Free cash flow: −27.0%

Quarter to June 2026, against a year earlier

Insider buying

18.78 0.87 +4.86%

Follow IMNM

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −7.6×
Dividend yield: —
F-score: 4/9
Altman Z: 21.57
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 2.10

Sold, $m 27.51

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	4	—	—	2	—	1	—	—	—	—	—	—
Sell	1	—	—	1	2	—	4	3	3	1	—	—

Insider Ownership 4.47%

Capital & Financial Ratios $m

Size

Market Cap 2,110.00

Revenue ttm 12.59

Net income ttm (254.32)

Free cash flow ttm (219.09)

Net debt Q (520.00)

Valuation

P/E 0.00

Forward P/E (7.63)

Price / sales 162.50

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.90

Financial health

Current ratio Q 15.08

Debt / equity Q 0.00

Interest coverage Q (16.09)

Growth

Revenue growth Q +69.84%

Operating income growth Q −68.11%

EPS, this year +2.75%

EPS, next year A −6.22%

Revenue, next year A −96.16%

EPS, past 5 yrs —

EPS, next 5 yrs A +12.49%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 64.40%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	138	217	653	520
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	145	221	661	538

	2023	2024	2025	Q'26
Payables	3	14	3	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	22	54	45	36

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	72.66%	236.47%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.51 Actual −0.65

−0.79 −0.70 −0.61 −0.53 −0.44

Q3 FY25 Miss −0.08

Q4 FY25 Miss −0.10

Q1 FY26 Beat +0.12

Q2 FY26 Miss −0.14

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.57	−0.65	Miss by 0.08
Q4 FY25	−0.65	−0.75	Miss by 0.10
Q1 FY26	−0.60	−0.48	Beat by 0.12
Q2 FY26	−0.51	−0.65	Miss by 0.14
Q3 FY26	−0.67	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.48)	(0.65)	—	—	—
’25	(0.52)	(0.50)	(0.65)	(0.75)	(2.43)
’24	(2.51)	(0.60)	(0.78)	(1.28)	(5.00)
’23	(0.35)	(0.46)	(0.36)	(4.22)	(5.38)
’22	(0.96)	(0.74)	(0.75)	(0.64)	(3.09)
’21	(0.37)	(0.46)	(0.65)	(0.66)	(2.14)
’20	(2.44)	(2.46)	(7.52)	(0.40)	(5.26)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	3	4	—	—	7
’24	1	2	3	3	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(59)	(62)	—	—	—
’25	(53)	(49)	(41)	(48)	(191)
’24	(11)	(23)	(34)	(42)	(111)
’23	24	(6)	(9)	(17)	(8)
’22	(6)	(8)	(8)	(7)	(29)
’21	(4)	(4)	(4)	(7)	(18)
’20	(2)	(1)	(3)	(6)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(62)	(64)	—	—	—
’25	(57)	(50)	(42)	(52)	(201)
’24	(13)	(26)	(36)	(43)	(118)
’23	24	(6)	(9)	(18)	(8)
’22	(6)	(8)	(8)	(7)	(29)
’21	(4)	(4)	(4)	(7)	(18)
’20	(2)	(2)	(3)	(6)	(13)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	14	9	7	13		(29.6%)	0	50	203	+207.9%
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack Immunome, Inc.’s next three years, line by line Analysts expect revenue to grow 207.9% a year to 2028 — faster than the −29.6% of the last 2 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	(8)	(10)	(18)	(25)	(37)	(107)	(293)	(212)	(254)		+60.2%
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	(761.92)	(3,240.38)	(3,059.99)	0.00		(3,060.0) pt
	Net income	—	0	(8)	(10)	(18)	(25)	(37)	(107)	(293)	(212)	(254)		n/m
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.71	0.15	0.08	0.00		n/m
	Earnings	—	—	(7.22)	(9.55)	(5.26)	(2.14)	(3.09)	(5.38)	(5.00)	(2.43)	(2.53)		(14.4%)
	Cash flow	—	—	(6.81)	(8.78)	(3.58)	(1.58)	(2.37)	(0.38)	(1.89)	(2.19)	(1.84)		(15.0%)
	Capex	—	—	(0.21)	(0.21)	(0.17)	(0.01)	(0.02)	(0.04)	(0.12)	(0.11)	(0.09)		(8.7%)
	Free cash flow	—	—	(7.02)	(8.99)	(3.75)	(1.59)	(2.39)	(0.42)	(2.01)	(2.30)	(1.93)		(14.8%)
	Book value	—	—	2.12	2.98	12.20	4.18	1.37	6.04	3.09	7.26	4.64		+19.2%
	Shares, m	—	—	1	1	3	12	12	20	59	87	100		+87.1%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	—	—	—	15.59	68.88	149.04	162.50		77.8
	P/B	—	—	—	—	—	—	—	1.82	3.44	2.96	3.90		2.7
	EV/Sales	—	—	—	—	—	—	—	5.77	44.90	97.17	121.23		49.3
	EV/FCF	—	—	—	—	—	—	—	(9.62)	(3.44)	(6.10)	(6.97)		(6.4)
Cash, $m
Cash, $m	Operating cash flow	—	—	(7)	(10)	(12)	(18)	(29)	(8)	(111)	(191)	(209)		+59.1%
	Capex	—	—	0	0	(1)	0	0	(1)	(7)	(10)	(10)		+70.8%
	Free cash flow	—	—	(8)	(10)	(13)	(18)	(29)	(8)	(118)	(201)	(219)		+59.5%
Balance, $m
Balance, $m	Working capital	—	—	1	1	40	47	15	123	167	616	503		+172.6%
	Net debt	—	—	0	(2)	(39)	(49)	(20)	(138)	(217)	(653)	(520)		+185.2%
	Shareholders’ equity	—	—	2	3	41	48	17	120	181	634	525		+123.1%
Returns, %
Returns, %	ROA	—	—	(352.74)	(219.69)	(71.95)	(48.24)	(91.54)	(123.77)	(150.71)	(46.00)	(59.03)		+306.7 pt
	ROIC	—	—	(257.14)	(503.31)	(368.60)	0.00	0.00	0.00	0.00	0.00	(3,322.99)		+257.1 pt
	ROE	—	—	25.79	34.34	(624.22)	(55.20)	(115.73)	(156.45)	(194.63)	(52.09)	(64.03)		(77.9) pt
People
People	Employees	—	—	—	21	23	39	37	55	118	177	—		+42.7%
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.25	0.08	0.04	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2025

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADMA ADMA Biologics Inc	$3.0B	16.7×	14.0×	+5.12% (above 0%: growing)	+46.67% (above 0%: growing)	+1,709.49% (above 0%: growing)	70.81%	48.02%	Compare
VCEL Vericel Corporation	$2.7B	77.8×	72.9×	+26.47% (above 0%: growing)	+180.00% (above 0%: growing)	−19.39% (below 0%: shrinking)	73.34%	14.27%	Compare
PVLA Palvella Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)	Compare
LKFT Lakefront Biotherapeutics - Sponsored ADR	$2.2B	— (loss-making)	— (loss-making)	−95.35% (below 0%: shrinking)	+198.85% (above 0%: growing)	+18.22% (above 0%: growing)	25.95%	(982.91%)	Compare
VERA Vera Therapeutics, Inc.	$2.2B	— (loss-making)	—	—	n/m	−82.47% (below 0%: shrinking)	0.00%	0.00%	Compare
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.8×	17.6×	+13.93% (above 0%: growing)	0.00%	+4.41% (above 0%: growing)	90.08%	40.74%	Compare
IMNM Immunome, Inc.	$2.1B	— (loss-making)	— (loss-making)	+69.84% (above 0%: growing)	n/m	−26.96% (below 0%: shrinking)	100.00%	0.00%
BHVN Biohaven Ltd.	$2.1B	— (loss-making)	— (loss-making)	+131.43% (above 0%: growing)	n/m	+26.55% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$2.2B	16.7×	17.6×	+5.12%	+113.34%	−7.49%	72.08%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	7.68m	28.07m	200.75
2024	9.23m	8.41m	99.25

Ownership

Directors and executive officers, together 7.21%

Entities affiliated with FMR LLC 11.54%

Entities affiliated with T. Rowe Price Investment Management, Inc. 9.41%

Entities affiliated with Redmile Group LLC 5.05%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Immunome, Inc. (IMNM) Latest News

4 Nov

Impact 3 · 9:01 AM · Business Wire

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026

2 Nov

Impact 3 · 6:14 PM · Simply Wall St.

Immunome Stock Gets EMA Review For Desmoid Tumor Drug

30 Oct

Impact 4 · 7:30 AM · Business Wire

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

26 Oct

Impact 4 · 7:00 AM · Business Wire

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

13 Oct

Impact 4 · 6:16 PM · Simply Wall St.

Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus

2 Oct

Impact 3 · 9:10 AM · Simply Wall St.

Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?

1 Oct

Impact 4 · 5:11 AM · Simply Wall St.

Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues

30 Sep

Impact 4 · 7:45 AM · Business Wire

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

11 Aug

Impact 3 · 4:02 PM

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

20 Jul

Impact 3 · 7:30 AM

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

12 Jul

Impact 4 · 5:04 PM · The Motley Fool

What This Immunome Sale Means a Day Before a Big FDA Milestone

10 Jul

Impact 3 · 10:40 AM

Immunome Stock Up 32% in a Month: Here's What You Should Know

8 Jul

Impact 4 · 7:30 AM

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

11 Jun

Impact 3 · 7:30 AM

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

4 Jun

Impact 4 · 10:13 PM · Simply Wall St.

Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?

30 May

Impact 4 · 8:00 AM · Business Wire

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

18 May

Impact 3 · 8:54 AM · Insider Monkey

What Offers Immunome (IMNM) a Compelling Investment Opportunity?

12 May

Impact 3 · 4:02 PM · Business Wire

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

11 May

Impact 5 · 3:13 AM · Simply Wall St.

Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success

Impact 4 · 8:01 PM · Insider Monkey

Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors

29 Apr

Impact 4 · 7:30 AM · Business Wire

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

25 Apr

Impact 5 · 7:04 AM · Simply Wall St.

A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing

21 Apr

Impact 4 · 10:30 AM

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

4 Apr

Impact 4 · 7:25 PM · The Motley Fool

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

6 Mar

Impact 4 · 5:11 PM · Simply Wall St.

Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative?

4 Mar

Impact 3 · 12:32 PM · The Motley Fool

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

3 Mar

Impact 4 · 4:02 PM · Business Wire

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

2 Mar

Impact 4 · 2:57 AM · Insider Monkey

Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development

22 Feb

Impact 4 · 1:23 PM · The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

13 Feb

Impact 4 · 11:03 PM · MarketBeat

Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Immunome, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 24 April 2026

Chief executive’s pay

Ownership

Immunome, Inc. (IMNM) Latest News

4 Nov

2 Nov

30 Oct

26 Oct

13 Oct

2 Oct

1 Oct

30 Sep

11 Aug

20 Jul

12 Jul

10 Jul

8 Jul

11 Jun

4 Jun

30 May

18 May

12 May

11 May

29 Apr

25 Apr

21 Apr

4 Apr

6 Mar

4 Mar

3 Mar

2 Mar

22 Feb

13 Feb

IMNM metrics, ten years each

Stockrow Weekly